Corbus Pharmaceuticals Holdings, Inc.

Contributing Author

Recent Articles by Corbus Pharmaceuticals Holdings, Inc.

Dec-11	Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss CRBP GlobeNewswire
Dec-10	Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 CRBP GlobeNewswire
Nov-12	Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update CRBP GlobeNewswire
Nov-06	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences CRBP GlobeNewswire
Oct-31	Corbus Pharmaceuticals Announces Pricing of Public Offering CRBP GlobeNewswire
Oct-30	Corbus Pharmaceuticals Announces Proposed Public Offering CRBP GlobeNewswire
Oct-18	Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25 CRBP GlobeNewswire
Oct-14	Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025 CRBP GlobeNewswire
Oct-07	Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium CRBP GlobeNewswire
Sep-22	Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025 CRBP GlobeNewswire
Sep-16	FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma CRBP GlobeNewswire
Aug-05	Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update CRBP GlobeNewswire
Jul-30	Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress CRBP GlobeNewswire
Jun-30	Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity CRBP GlobeNewswire
Jun-25	Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab CRBP GlobeNewswire
Jun-24	Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium CRBP GlobeNewswire
May-22	Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference CRBP GlobeNewswire
May-19	Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair CRBP GlobeNewswire
May-08	Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference CRBP GlobeNewswire
May-06	Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update CRBP GlobeNewswire

Corbus Pharmaceuticals Holdings, Inc.

Recent Articles by Corbus Pharmaceuticals Holdings, Inc.

Upgrade your FINVIZ experience